News & Updates

Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

Weight loss during adulthood, particularly among overweight or obese individuals, is associated with a reduction in the risk of developing distal colorectal adenomas – a precursor to colorectal cancer, whereas weight gain increased its risk, according to findings from the PLCO* Cancer Screening Trial.

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.